中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2013年
12期
75-76
,共2页
阿奇霉素%红霉素%序贯疗法%小儿支原体肺炎
阿奇黴素%紅黴素%序貫療法%小兒支原體肺炎
아기매소%홍매소%서관요법%소인지원체폐염
Azithromycin%Erythromycin%Sequential therapy%Mycoplasma pneumonia
目的比较阿奇霉素序贯疗法与红霉素对小儿支原体肺炎(MP)的临床疗效及用药安全性。方法将我院2010年11月~2012年11月收治的36例MP患者按随机数字表格法分为治疗组与对照组,两组患儿入院后均给予退热、平喘、止咳化痰等常规对症治疗。对照组在常规治疗基础上使用红霉素,治疗组使用阿奇霉素序贯治疗。结果治疗组和对照组的总有效率分别为94.4%、83.3%,两组比较差异具有统计学意义(P<0.05);治疗组患儿的退热时间、肺部啰音持续时间及平均住院时间分别为(3.20±1.74)d、(5.71±2.13)d、(8.28±1.64)d,均明显短于对照组(P<0.05);治疗组药物不良反应发生率也明显低于对照组(P<0.05)。结论阿奇霉素序贯疗法治疗小儿MP较红霉素效果更佳,更具安全性。
目的比較阿奇黴素序貫療法與紅黴素對小兒支原體肺炎(MP)的臨床療效及用藥安全性。方法將我院2010年11月~2012年11月收治的36例MP患者按隨機數字錶格法分為治療組與對照組,兩組患兒入院後均給予退熱、平喘、止咳化痰等常規對癥治療。對照組在常規治療基礎上使用紅黴素,治療組使用阿奇黴素序貫治療。結果治療組和對照組的總有效率分彆為94.4%、83.3%,兩組比較差異具有統計學意義(P<0.05);治療組患兒的退熱時間、肺部啰音持續時間及平均住院時間分彆為(3.20±1.74)d、(5.71±2.13)d、(8.28±1.64)d,均明顯短于對照組(P<0.05);治療組藥物不良反應髮生率也明顯低于對照組(P<0.05)。結論阿奇黴素序貫療法治療小兒MP較紅黴素效果更佳,更具安全性。
목적비교아기매소서관요법여홍매소대소인지원체폐염(MP)적림상료효급용약안전성。방법장아원2010년11월~2012년11월수치적36례MP환자안수궤수자표격법분위치료조여대조조,량조환인입원후균급여퇴열、평천、지해화담등상규대증치료。대조조재상규치료기출상사용홍매소,치료조사용아기매소서관치료。결과치료조화대조조적총유효솔분별위94.4%、83.3%,량조비교차이구유통계학의의(P<0.05);치료조환인적퇴열시간、폐부라음지속시간급평균주원시간분별위(3.20±1.74)d、(5.71±2.13)d、(8.28±1.64)d,균명현단우대조조(P<0.05);치료조약물불량반응발생솔야명현저우대조조(P<0.05)。결론아기매소서관요법치료소인MP교홍매소효과경가,경구안전성。
Objective To compare clinical efficacy and safety of azithromycin sequential therapy with erythromycin mycoplasma pneumonia (MP) in drug use. Methods In our hospital from November 2010 to November 2012 were treated 36 cases of patients with MP random number table is divided into the treatment group and the control group, two groups of children were given after admission fever, asthma,cough and phlegm and other conventional symptomatic treatment.Control group on the basis of conventional therapy with erythromycin, azithromycin sequential therapy treatment group. Results The treatment group and the control group the total effective rate was 94.4%, 83.3%, the difference was statistically significant (P<0.05);treatment group of children with fever, pulmonary rales, duration and average hospital stay was (3.20 ± 1.74) d,(5.71 ± 2.13) d, (8.28 ± 1.64) d, were significantly shorter than the control group (P < 0.05); treatment group, the incidence of adverse drug reactions was significantly lower than the control group (P < 0.05). Conclusion azithromycin sequential therapy in the treatment of pediatric MP than erythromycin better, more secure.